Company news
Enveric Biosciences, Inc. news in 2026
Enveric Biosciences, Inc.'s news releases, calls and decks from 2026, newest first.
Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study
November 4, 2026
Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies
October 21, 2026
Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
September 15, 2026
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
September 1, 2026
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
August 14, 2026
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
August 5, 2026
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
July 27, 2026
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
June 29, 2026
Enveric Biosciences Announces Participation in 2026 BIO International Convention
June 16, 2026
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
June 8, 2026
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
June 1, 2026
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
May 19, 2026
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
May 15, 2026
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
May 13, 2026
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
May 5, 2026
Enveric Biosciences to Participate in a Panel Discussion at Needham’s Virtual Psychedelics Forum
April 21, 2026
Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
April 17, 2026
Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
April 16, 2026
Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates
March 30, 2026
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025
March 27, 2026
Enveric Biosciences Announces Registration of Five Trademarks
March 17, 2026
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent
February 24, 2026
Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data
February 19, 2026
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option
January 29, 2026
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
January 28, 2026
Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
January 28, 2026
Decks in 2026
- Investor Presentation (June 2026)
Investor deck · 15 slides · Jun 9, 2026
- Investor Presentation (January 2026)
Investor deck · 17 slides · January 2026